CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 55 enrolled
Drug / intervention
Placebo +1 moredrug
Likely dose
Bromocriptine-QR 1.6mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05405244
NCT05405244Phase 3Completed
CompareCT.gov

A Multimodel Examination of Bromocriptine on Homeostatic and Hedonic Mechanisms of Food Intake in Individuals at High Risk for Type 2 Diabetes

University of North Carolina, Chapel Hill·interventional·Posted Jun 6, 2022·Updated Sep 7, 2022

In Brief

A Phase 3 clinical trial evaluating Placebo and Bromocriptine-QR for Overweight and Obesity and Eating Behavior. Completed, enrolled 55 participants across 1 site.

Detailed Summary

The current project applies an integrative three-prong approach to investigate the potential of the dopamine D2 receptor (DRD2) agonist bromocriptine to: 1) increase homeostatic satiation signaling, 2) alter neural circuitry to reduce hedonically motivated food intake, and 3) examines a genetic predisposition that may markedly impact the effectiveness of this medication in those at high risk for T2DM.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOverweight and Obesity, Eating Behavior
CountriesUnited States
CollaboratorsAmerican Diabetes Association

Timeline

Phase 3CompletedFinished
201820192020202120222023202420252026
First PostedJun 6, 2022
Enrollment StartSep 19, 2017
Primary CompletionSep 19, 2019
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 4.1 years ago

Interventions

Placebodrug

2 capsules, orally administered once

Bromocriptine-QRdrug

1.6mg (2 0.8mg capsules), orally administered once